Phase II study of first-line ¹³¹I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic ¹⁸F-fluorodeoxyglucose positron emission tomography

References

• Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the National LymphoCare study. J Clin Oncol 2009;27:1202–1208.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362:516–522.
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1997;15:1110–1117.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42–51.
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Cheson BD. Current role of FDG PET/CT in lymphoma. Eur J Nucl Med Mol Imaging 2014;41:1004–1027.
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius J, Skoetz N, et al. Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev 2007;(7):CD003805.
   Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203–1210.
   PubMed Web of Science ®Google Scholar
• Lanini S, Molloy AC, Fine PE, et al. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med 2011;9:36.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Estey E, Glassman A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 2005;105:4573–4575.
   PubMed Web of Science ®Google Scholar
• Pirani M, Marcheselli R, Marcheselli L, et al. Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. Ann Oncol 2011;22:1845–1858.
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337.
   PubMed Web of Science ®Google Scholar
• Hadjinicolaou AV, Nisar MK, Parfrey H, et al. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford) 2012;51:653–662.
   PubMed Web of Science ®Google Scholar
• Hoppe S, Rainfray M, Fonck M, et al. Functional decline in older patients with cancer receiving first-line chemotherapy. J Clin Oncol 2013;31:3877–3882.
   PubMed Web of Science ®Google Scholar
• Baudino B, D’Agata F, Caroppo P, et al. The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients. Q J Nucl Med Mol Imaging 2012;56:559–568.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Tuck M, Estes J, et al. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: median 10 year follow-up results. Blood 2009;114(Suppl. 1): Abstract 3759.
   Google Scholar
• Illidge TM, Mayes S, Pettengel R, et al. Fractioned 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria. J Clin Oncol 2014;32:212–218.
   PubMed Web of Science ®Google Scholar
• Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10 year single institution experience in 142 consecutive patients. Blood 2011;117:45–52.
   PubMed Web of Science ®Google Scholar
• Tychyj-Pinel C, Ricard F, Fulham M, et al. PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. Eur J Nucl Med Mol Imaging 2014;41:408–415.
   PubMed Web of Science ®Google Scholar
• Trotman J, Fournier M, Lamy T, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 2011;29:3194–3200.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Mikhaeel NG. Imaging follicular lymphoma using positron emission tomography with [18F] fluorodeoxyglucose: to what purpose? J Clin Oncol 2012;30:4285–4287.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Meignan M, Gallamini A, Meignan M, et al. Report on the First International Workshop on interim-PET scan in lymphoma. Leuk Lymphoma 2009;50:1257–1260.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
   Google Scholar
• Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Boellard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181–200.
   PubMed Web of Science ®Google Scholar
• Illidge TM, Bayne M, Brown NS, et al. Phase study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 2009;113:1412–1421.
   PubMed Web of Science ®Google Scholar
• Turner JH, Martindale AA, Boucek J, et al. 131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma: a phase II clinical trial of non-myeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm 2003;18:513–524.
   PubMed Web of Science ®Google Scholar
• Calais PJ, Turner JH. Outpatient 131I-rituximab radioimmunotherapy for non-Hodgkin lymphoma. Clin Nucl Med 2012;37:732–737.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. Published 28 May 2009 (v4.03: 14 June 2010). Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html
   Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725–3732.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisolone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579–4586.
   PubMed Web of Science ®Google Scholar
• Press OW, Unger JM, Rimsza LM, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 2013;31:314–320.
   PubMed Web of Science ®Google Scholar
• Smith SM. Dissecting follicular lymphoma: high versus low risk. Hematology Am Soc Educ Program 2013:561–567.
   Google Scholar
• Dupuis J, Berriolo-Riedinger A, Julian A, et al. Impact of [18F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS. J Clin Oncol 2012;30:4317–4322.
   PubMed Web of Science ®Google Scholar
• Lopci E, Zanoni L, Chiti A, et al. FDG PET/CT predictive role in follicular lymphoma. Eur J Nucl Med Mol Imaging 2012;39:864–871.
   PubMed Web of Science ®Google Scholar
• Han HS, Escalón MP, Hsiao B, et al. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol 2009;20:309–318.
   PubMed Web of Science ®Google Scholar
• Bishton MJ, Leahy MF, Hicks RJ, et al. Repeat treatment with iodine-131 rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkins's lymphoma who had previously responded to iodine-131 rituximab. Ann Oncol 2008;19:1629–1633.
   PubMed Web of Science ®Google Scholar
• Kothari J, Pegg KS, Bird A, et al. Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure. Br J Haematol 2014;165:334–340.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine 131 tositumomab. Blood 2005;10:4576–4582.
   Web of Science ®Google Scholar
• Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 2007;25:4285–4292.
   PubMed Web of Science ®Google Scholar